Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan and rituximab,
can locate cancer cells and either kill them or deliver radioactive cancer-killing substances
to them without harming normal cells. Combining yttrium Y 90 ibritumomab tiuxetan with
rituximab may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining yttrium Y 90 Ibritumomab
tiuxetan with rituximab in treating patients who have relapsed or refractory diffuse large
B-cell non-Hodgkin's lymphoma.